Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · True Rheumatic Emergencies · Free · No registration

Fulminant autoimmune myocarditis

Recognize shock and electrical instability, support the heart and identify immune subtypes that change urgent treatment.

Clinically reviewed: October 4, 2026 · Free to read · English

1. Identify pump failure and electrical danger

Fulminant myocarditis is an acute inflammatory myocardial presentation with hemodynamic instability requiring inotropic or mechanical circulatory support. Escalate before that definition is fully met when perfusion and heart failure are rapidly worsening. Sustained ventricular arrhythmia or high-grade atrioventricular block is a separate cardiac emergency that can occur with preserved left ventricular ejection fraction.

Assess mental state, extremity perfusion, blood pressure, urine output, congestion and respiratory support together. Chest pain, syncope, palpitations or rapidly worsening breathlessness in a patient with lupus, EGPA or inflammatory myopathy should raise concern, but an autoimmune diagnosis does not establish the cause of today’s cardiac event.

Shock, unstable rhythm, advanced conduction disease or severe pulmonary edema requires emergency cardiac/critical-care management. Use monitored transport and early contact with an advanced-heart-failure center when local support is limited. The ACC pathway emphasizes both hemodynamic and electrical instability when identifying the highest-risk presentation.

Pump and rhythm threats → Professional access required

2. Investigate while providing cardiac support

Obtain a 12-lead ECG, continuous rhythm monitoring, vascular access and urgent bedside echocardiography. Review left and right ventricular function, regional abnormalities, valves, pericardial fluid and hemodynamic findings. Arrange immediate defibrillation or pacing capability when the presentation requires it. Repeat perfusion assessment after every clinically important support change. The AHA fulminant-myocarditis statement supports early involvement of a shock team to coordinate vasoactive treatment, mechanical-support options and transfer. Device selection depends on ventricular involvement, oxygenation and the likely bridge to recovery or transplantation; it cannot be chosen from ejection fraction alone.

Measure serial troponin with assay and collection times, blood count with differential, kidney and liver function, potassium and magnesium. Add natriuretic peptides, lactate, blood gases, cultures and targeted infection studies according to the clinical question. Retrieve previous ECGs, imaging, eosinophil counts and medication exposure, including immune checkpoint inhibitors.

Keep acute coronary syndrome, coronary thrombosis, pulmonary embolism, tamponade, sepsis and toxic cardiomyopathy active in the differential. Known autoimmune disease must not delay indicated coronary assessment or reperfusion. A patient can have inflammatory disease and another cardiac emergency simultaneously. Troponin identifies myocardial injury in context; its magnitude does not independently determine the care setting.

Immediate assessment and competing emergencies → Professional access required

3. Choose CMR and biopsy for different questions

Cardiac magnetic resonance (CMR) can characterize edema, injury and scar when transport and monitoring are safe. It complements ECG, echocardiography and coronary assessment. It must not postpone circulatory rescue, and it cannot reliably establish every histologic subtype that changes urgent treatment.

The 2025 ESC guideline supports early endomyocardial biopsy in selected fulminant or high-risk presentations when tissue can identify an actionable cause. Coordinate histology, immunohistochemistry and appropriate molecular studies with an experienced center. Biopsy is not routine for every stable suspected case; sampling error means a nondiagnostic specimen does not always settle persistent high-risk concern.

Giant-cell, eosinophilic and immune checkpoint inhibitor-associated myocarditis are particularly important etiologic considerations. Obtain samples before immunosuppression when immediately feasible, but do not allow an extended diagnostic sequence to delay necessary treatment of a strongly suspected, rapidly fatal immune subtype. Document the working diagnosis and the specific question tissue is expected to answer.

CMR, coronary evaluation and biopsy → Professional access required

4. Avoid reassuring snapshots and assay shortcuts

One normal ECG, troponin or echocardiogram does not exclude myocarditis when suspicion remains high. Preserved global ejection fraction does not exclude right ventricular disease, dangerous arrhythmia or conduction block. Reassess the clinical trajectory rather than using any single measurement as clearance for discharge.

Absence of peripheral eosinophilia does not exclude eosinophilic myocardial disease, especially after glucocorticoids. Review historical counts and the full phenotype, including asthma, sinus disease, neuropathy, rash and drug exposure. Eosinophilic myocarditis can arise from causes other than EGPA, including hypersensitivity and selected infections.

In active skeletal myositis, troponin T can have a noncardiac contribution. The prospective skeletal-muscle-disorder study supports considering troponin I and assay discordance alongside symptoms, ECG and imaging. Its largely elective population does not validate dismissing an acute troponin rise or clinical instability. Neither “definite myocarditis” nor “only skeletal muscle” follows from troponin T alone.

Troponin and recognition traps → Professional access required

5. Match immunotherapy to the phenotype

Circulatory and rhythm support continues while cardiology, rheumatology and relevant specialists establish the cause. Do not administer pulse glucocorticoids automatically for every undifferentiated biomarker rise. Conversely, strong suspicion of an actionable immune subtype can require urgent immune treatment while testing proceeds.

For acute or worsening lupus myocarditis, the 2025 ACR SLE guideline conditionally supports glucocorticoids with additional immunosuppression and/or IVIG rather than glucocorticoids alone. Regimen choice depends on severity, other organ disease and patient factors. The 29-patient lupus myocarditis series documents varied treatment and outcomes; it does not establish one superior induction regimen.

For severe EGPA with active cardiac involvement, ACR/Vasculitis Foundation guidance supports glucocorticoids plus cyclophosphamide or rituximab, favoring cyclophosphamide for cardiac disease because of greater experience. Mepolizumab does not replace induction for life-threatening organ disease.

Giant-cell myocarditis requires urgent expert assessment, combination immunosuppression and mechanical-support/transplant planning; steroid monotherapy is inadequate as a definitive strategy. Suspected checkpoint inhibitor myocarditis requires holding the drug and immediate cardio-oncology assessment, with prompt specialist corticosteroid treatment for strongly suspected unstable disease. Assess accompanying myositis or myasthenic features, including bulbar and respiratory weakness. Ask about ptosis, diplopia, dysphagia and neck weakness. A reassuring pulse-oximetry reading does not measure respiratory muscle reserve. Neurology and respiratory teams may need to assess ventilation and airway protection while cardiac immunotherapy proceeds.

Phenotype-specific immune treatment → Professional access required

6. Measure response across organs and plan follow-up

Follow perfusion, vasoactive requirements, urine output, rhythm, conduction, respiratory support and ventricular function together. A falling troponin does not prove recovery from shock. Recurrent arrhythmia or increasing support requires immediate reassessment, potentially including temporary mechanical circulatory support or review of tissue diagnosis.

During immunotherapy, monitor infection, glucose, blood pressure, fluid balance, electrolytes and cytopenias according to the regimen. Systemic sclerosis overlap requires explicit consideration of renal-crisis risk. NSAIDs or colchicine for pericardial pain do not treat cardiogenic shock; chronic heart-failure medication decisions must account for active hemodynamic and conduction instability.

After stabilization, name cardiac and rheumatology follow-up responsibility, assign pending biopsy results and document immune-treatment tapering and toxicity surveillance. Recovered ejection fraction alone does not settle arrhythmia risk. Arrange repeat imaging and rhythm assessment, rehabilitation and return precautions. Record the actual cardiac phenotype, including prior ventricular arrhythmia or pacing requirements, so a later clinician does not infer low risk from a recovered scan.

Avoid strenuous exercise during active myocarditis. Return requires clinical recovery and cardiology reassessment rather than an automatic calendar date. Explain that syncope, sustained palpitations, chest pain or recurrent breathlessness requires prompt reassessment, even if the previous scan appeared reassuring.

Response, surveillance and onward care → Professional access required

Selected sources

Clinical review: October 4, 2026. This independent overview accompanies the full professional emergency module.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology